Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
APAF1
REST API REST API
Homo sapiens
APAF1 is differentially expressed in 275 experiments: 121 organism parts: lung, skeletal muscle, ... (119 more);, 208 disease states: normal, glioblastoma, ... (206 more);, 93 cell types 350 cell lines 43 compound treatments and 69 other conditions.
Synonyms APAF-1, CED4
Orthologs apaf1 (Danio rerio)   Apaf1 (Mus musculus)   PRP4 (Saccharomyces cerevisiae)   APAF1 (Gallus gallus)   APAF1 (Bos taurus)   D3ZA56_RAT (Rattus norvegicus)   apaf1 (Xenopus laevis)   APAF_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, protein binding, apoptosis, cytoplasm, apoptotic protease activator activity, intracellular, Golgi apparatus, activation of caspase activity, activation of caspase activity by cytochrome c, soluble fraction, identical protein binding, ATP binding, defense response, multicellular organismal development, nucleus, caspase activator activity, nucleotide binding, nervous system development, DNA fragmentation involved in apoptotic nuclear change, brain development, neuron apoptosis, regulation of apoptosis, neural tube closure, apoptosome, forebrain development, ADP binding, induction of apoptosis by intracellular signals, positive regulation of peptidase activity
InterPro Term WD40_repeat_dom, WD40_repeat, Disease_R, WD40_repeat_2, NB-ARC, CARD, Apoptotic_pept-activating_1, G-protein_beta_WD-40_rep, WD40_repeat_subgr
UniProt Accession O14727, F8VNZ0, C9JLV4
Search EB-eye ENSG00000120868
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-AFMX-5, E-MEXP-1251, E-MTAB-24, E-MTAB-25, ... (23 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, E-GEOD-2450, ... (35 experiments)

Factor Value U/D Experiments
MDA468
2
E-MEXP-440, E-MTAB-62
Jurkat
2
E-MEXP-2197, E-GEOD-1880
HCC1143
2
E-MTAB-37, E-MTAB-62
MCF-7
2
E-GEOD-5823, E-GEOD-20081
HL-60
1
2
E-GEOD-5258, E-MTAB-37, E-GEOD-24147
AN3CA
1
E-MTAB-37
344 more value(s).


Cell type

studied in E-GEOD-22373, E-GEOD-21668, E-GEOD-3920, E-MEXP-66, E-GEOD-4219, ... (46 experiments)

Factor Value U/D Experiments
monocyte
3
E-GEOD-22373, E-MEXP-583, E-GEOD-8286
fibroblast
3
E-GEOD-3204, E-GEOD-3920, E-GEOD-26672
testis - germ cell
2
E-AFMX-5, E-TABM-145
CD33+ myeloid
2
E-AFMX-5, E-TABM-145
endothelial cell
1
2
E-GEOD-19240, E-GEOD-3920, E-GEOD-3998
centroblast
1
E-GEOD-15271
87 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-1577, E-MTAB-62, E-GEOD-5370, ... (54 experiments)

Factor Value U/D Experiments
adenocarcinoma
2
E-MTAB-62, E-MTAB-37
lung carcinoma
2
E-MTAB-37, E-GEOD-6014
adrenocortical carcinoma
2
E-GEOD-10927, E-TABM-311
colon carcinoma
2
E-MTAB-62, E-GEOD-3726
melanoma
2
E-MTAB-62, E-MTAB-37
multiple myeloma
2
E-MTAB-62, E-GEOD-6691
202 more value(s).


Compound treatment

studied in E-GEOD-1615, E-GEOD-7400, E-GEOD-5258, E-GEOD-5741, E-TABM-782, ... (26 experiments)

Factor Value U/D Experiments
none
3
6
E-GEOD-412, E-GEOD-5824, E-MEXP-1269, E-GEOD-7400, E-TABM-782, ... (9 experiments)
valproic acid
1
E-GEOD-1615
M-CSF
1
1
E-GEOD-5099
endotoxin
1
E-GEOD-2322
AMP
1
1
E-MEXP-2285
NaOH
1
E-MEXP-2590
37 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
1
E-GEOD-19519
thapsigargin
1
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-19420, E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21374, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-MEXP-1251, E-GEOD-21374, ... (9 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-3140, E-MEXP-2359, E-GEOD-2666, E-MTAB-62 ... (5 experiments)

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-TABM-147, E-GEOD-21138, E-GEOD-19665, ... (6 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-3720

Epiregulin elisa conc ng ml
studied in E-GEOD-5851

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-1643, E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MEXP-1482, E-GEOD-7578, E-GEOD-20847

Genotype
studied in E-GEOD-17476, E-GEOD-21750, E-MEXP-421, E-GEOD-22593, E-TABM-321, ... (10 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-5681, E-GEOD-7011, E-TABM-127, E-GEOD-20540, ... (8 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-1926, E-MEXP-1648, E-TABM-15, ... (33 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-GEOD-17400

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-GEOD-2004, E-LGCL-5

Phenotype
studied in E-GEOD-19703, E-GEOD-21750, E-GEOD-1657, E-GEOD-1460

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Progression free survival of days
studied in E-GEOD-5851

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

pt
studied in E-GEOD-21653

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-GEOD-3697, E-MEXP-1857, ... (7 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-17400

Sex
studied in E-GEOD-22541, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Test result
studied in E-GEOD-1926

Treatment
studied in E-GEOD-22152, E-GEOD-16837, E-GEOD-21909, E-GEOD-19246, E-GEOD-19815, ... (6 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271

Processing time: 0.471 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM